Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mikacin
- Development stage
- Unknown
- Lead developer
- Merlin Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
Mikacin is a brand name for amikacin, a semi-synthetic aminoglycoside antibiotic manufactured by Merlin Pharmaceuticals (Merlin Pharma (P) Limited). It is a small molecule drug provided as an injectable formulation, available in various strengths such as 50 mg (Mikacin M 50) and 250 mg (Mikacin MP 250). Amikacin is bactericidal and exerts its effect by binding to the 30S ribosomal subunit of susceptible bacteria, specifically the 16S rRNA, which interferes with the initiation of protein synthesis and induces mRNA misreading. This drug is primarily indicated for the treatment of serious infections caused by multi-drug resistant Gram-negative bacteria, including *Pseudomonas aeruginosa*, *Escherichia coli*, and *Klebsiella* species, as well as certain mycobacterial infections.
- Brand names
- MikacinMikacin M 50Mikacin MP 250
- Other names
- amikacin
02
Targets
30S A-site (Bacterial ribosomal 30S A-site)23S rRNA P-site (23S rRNA peptidyl-transferase center P-site)Bridge B5 (Bacterial 70S ribosome intersubunit bridge B5)Bacterial 50S ribosomal subunit secondary rRNA/protein sites
Beyond the preview
Go deeper on Mikacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mikacin.